Hostname: page-component-8448b6f56d-t5pn6 Total loading time: 0 Render date: 2024-04-19T05:30:35.869Z Has data issue: false hasContentIssue false
  • English
  • Français

Testing for diabetes

Published online by Cambridge University Press:  02 January 2018

L. Citrome ,
A. Jaffe  and
J. Levine
L. Citrome
Affiliation:
New York University School of Medicine, Department of Psychiatry Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg NY 10962, USA
A. Jaffe
Affiliation:
New York University School of Medicine, Department of Psychiatry Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg NY 10962, USA
J. Levine
Affiliation:
New York University School of Medicine, Department of Psychiatry Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg NY 10962, USA
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Columns
Information
The British Journal of Psychiatry , Volume 186 , Issue 1 , January 2005 , pp. 78
Copyright
Copyright © 2005 The Royal College of Psychiatrists 

Taylor et al (Reference Taylor, Young and Esop2004) report on the differences in testing for diabetes among 606 patients receiving antipsychotics, observing that patients receiving atypical antipsychotics were more likely to have been tested than those receiving older agents. Moreover, this appeared to be significant specifically for clozapine, olanzapine, and antipsychotic polypharmacy.

It is noteworthy that very similar results were found by our group when examining hospitalised patients in New York State (Citrome et al, Reference Citrome, Jaffe and Levine2003, Reference Citrome, Jaffe and Levine2004). Among 1154 patients in 2000–2002 with no known prior history of receiving antidiabetic medications, those receiving clozapine, olanzapine, or more than one atypical antipsychotic had a significantly higher frequency of blood glucose testing than those receiving only typical antipsychotics (Reference Citrome, Jaffe and LevineCitrome et al, 2004). Moreover, those receiving risperidone had a frequency of testing similar to those receiving only older agents, resulting in the conclusion that there are clear differences in surveillance for diabetes mellitus among even the newer agents.

Investigators performing pharmaco-epidemiological studies examining the risk of association between antipsychotics and diabetes mellitus need to be mindful of this surveillance bias.

Footnotes

Declaration of interest

L.C. has received research support and/or honoraria for speaking on. advisory boards from Abbott, Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer and Repligen Corp. A.J. has received research. support from Eli Lilly.

References

Citrome, L., Jaffe, A., Levine, J., et al (2003) Antipsychotic medication treatment and new prescriptions for insulin and oral hypoglycaemics. European Neuropsychopharmacology, 13 (suppl. 4), S306.CrossRefGoogle Scholar
Citrome, L., Jaffe, A., Levine, J., et al (2004) Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatric Services, 55, 1006–1013.Google Scholar
Taylor, D., Young, C., Esop, R., et al (2004) Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. British Journal of Psychiatry, 185, 152–156.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.